Wells Fargo sees ‘room to run’ for Johnson & Johnson, highlights pharma upside

Wells Fargo upgraded Johnson & Johnson (JNJ) to Overweight from Equal Weight, raising its price target to $212 from $170, driven by attractive valuation and increased confidence in the company's pharmaceutical growth outlook. The bank noted JNJ's NTM P/E trades at a nearly 30% discount to the S&P 500, presenting an attractive entry point amid easing pricing risks and JNJ's $55 billion U.S. R&D and manufacturing commitment. Wells Fargo anticipates a 2025–2030 pharma sales CAGR of 7.7%, significantly above Street expectations, projecting substantial upside to consensus estimates.

Analysis

Wells Fargo has issued a significant upgrade for Johnson & Johnson (JNJ), raising its rating to Overweight and increasing its price target to $212, signaling strong conviction in the company's prospects. The rationale is twofold, focusing on valuation and a re-evaluated growth outlook. Currently, JNJ's forward P/E multiple trades at a nearly 30% discount to the S&P 500, a stark contrast to its 20-year average discount of just 5%, suggesting a historically attractive entry point. This valuation gap is seen as unjustified given Wells Fargo's increased confidence in JNJ's pharmaceutical division, which is expected to successfully navigate the impending loss of exclusivity for Stelara. The bank's proprietary forecast projects a 2025-2030 pharma sales CAGR of 7.7%, substantially higher than the consensus street estimate of 5.0%. This optimistic growth view, underpinned by JNJ's $55 billion commitment to U.S. R&D and manufacturing, could translate to nearly $8 billion in revenue upside versus consensus by 2030. Furthermore, easing regulatory pressures, exemplified by Pfizer's recent drug pricing deal, reduce a key overhang for the sector and for JNJ.

Key Decisions for Investors

• Given the historically wide valuation discount and a bullish, above-consensus growth forecast from a major bank, investors should consider this an opportune moment to initiate or add to long positions in JNJ.
• The primary thesis driver is the divergence between Wells Fargo's 7.7% pharma sales CAGR forecast and the Street's 5.0%; investors must monitor JNJ's quarterly pharma segment performance and guidance to validate this accelerated growth trajectory.
• Monitor developments around the Stelara patent cliff and the productivity of the company's drug pipeline, as the ability to offset this revenue loss is critical to realizing the projected upside and closing the valuation gap.